76 related articles for article (PubMed ID: 38745155)
1. FGFR2 mutations promote endometrial cancer progression through dual engagement of EGFR and Notch signalling pathways.
Dixit G; Gonzalez-Bosquet J; Skurski J; Devor EJ; Dickerson EB; Nothnick WB; Issuree PD; Leslie KK; Maretzky T
Clin Transl Med; 2023 May; 13(5):e1223. PubMed ID: 37165578
[TBL] [Abstract][Full Text] [Related]
2. Pentoxifylline and Norcantharidin Modify p62 Expression in 2D and 3D Cultures of B16F1 Cells.
González-Quiroz JL; Ocampo-Godínez JM; Hernández-González VN; Lezama RA; Reyes-Maldonado E; Vega-López A; Domínguez-López ML
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791178
[TBL] [Abstract][Full Text] [Related]
3. Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer.
Lau DK; Collin JP; Mariadason JM
Biomedicines; 2024 May; 12(5):. PubMed ID: 38791079
[TBL] [Abstract][Full Text] [Related]
4. FGFR2-triggered autophagy and activation of Nrf-2 reduce breast cancer cell response to anti-ER drugs.
Gorska-Arcisz M; Popeda M; Braun M; Piasecka D; Nowak JI; Kitowska K; Stasilojc G; Okroj M; Romanska HM; Sadej R
Cell Mol Biol Lett; 2024 May; 29(1):71. PubMed ID: 38745155
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of phase-separated p62 bodies by ULK1 activates a redox-independent stress response.
Ikeda R; Noshiro D; Morishita H; Takada S; Kageyama S; Fujioka Y; Funakoshi T; Komatsu-Hirota S; Arai R; Ryzhii E; Abe M; Koga T; Motohashi H; Nakao M; Sakimura K; Horii A; Waguri S; Ichimura Y; Noda NN; Komatsu M
EMBO J; 2023 Jul; 42(14):e113349. PubMed ID: 37306101
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen induces radioresistance through NRF2-mediated metabolic reprogramming in breast cancer.
Naumann FV; Sweep FCGJ; Adema GJ; Peeters WJM; Martens JWM; Bussink J; Span PN
Cancer Metab; 2023 Feb; 11(1):3. PubMed ID: 36755288
[TBL] [Abstract][Full Text] [Related]
7. Recent Advances in the Role of Autophagy in Endocrine-Dependent Tumors.
Komarla A; Dufresne S; Towers CG
Endocr Rev; 2023 Jul; 44(4):629-646. PubMed ID: 36631217
[TBL] [Abstract][Full Text] [Related]
8. Blockage of Nrf2 and autophagy by L-selenocystine induces selective death in Nrf2-addicted colorectal cancer cells through p62-Keap-1-Nrf2 axis.
Hsu WL; Wang CM; Yao CL; Chen SC; Nien CY; Sun YH; Tseng TY; Luo YH
Cell Death Dis; 2022 Dec; 13(12):1060. PubMed ID: 36539411
[TBL] [Abstract][Full Text] [Related]
9. Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Zingg D; Bhin J; Yemelyanenko J; Kas SM; Rolfs F; Lutz C; Lee JK; Klarenbeek S; Silverman IM; Annunziato S; Chan CS; Piersma SR; Eijkman T; Badoux M; Gogola E; Siteur B; Sprengers J; de Klein B; de Goeij-de Haas RR; Riedlinger GM; Ke H; Madison R; Drenth AP; van der Burg E; Schut E; Henneman L; van Miltenburg MH; Proost N; Zhen H; Wientjens E; de Bruijn R; de Ruiter JR; Boon U; de Korte-Grimmerink R; van Gerwen B; Féliz L; Abou-Alfa GK; Ross JS; van de Ven M; Rottenberg S; Cuppen E; Chessex AV; Ali SM; Burn TC; Jimenez CR; Ganesan S; Wessels LFA; Jonkers J
Nature; 2022 Sep; 609(7929):E13. PubMed ID: 36050473
[No Abstract] [Full Text] [Related]
10. An update of Nrf2 activators and inhibitors in cancer prevention/promotion.
Pouremamali F; Pouremamali A; Dadashpour M; Soozangar N; Jeddi F
Cell Commun Signal; 2022 Jun; 20(1):100. PubMed ID: 35773670
[TBL] [Abstract][Full Text] [Related]
11. FGF7/FGFR2-JunB signalling counteracts the effect of progesterone in luminal breast cancer.
Mieczkowski K; Kitowska K; Braun M; Galikowska-Bogut B; Gorska-Arcisz M; Piasecka D; Stawiski K; Zaczek AJ; Nejc D; Kordek R; Romanska HM; Sadej R
Mol Oncol; 2022 Aug; 16(15):2823-2842. PubMed ID: 35726195
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor receptor signalling dysregulation and targeting in breast cancer.
Francavilla C; O'Brien CS
Open Biol; 2022 Feb; 12(2):210373. PubMed ID: 35193394
[TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet Oncol; 2022 Mar; 23(3):382-392. PubMed ID: 35123662
[TBL] [Abstract][Full Text] [Related]
14. TBHQ attenuates ferroptosis against 5-fluorouracil-induced intestinal epithelial cell injury and intestinal mucositis via activation of Nrf2.
Deng S; Wu D; Li L; Li J; Xu Y
Cell Mol Biol Lett; 2021 Nov; 26(1):48. PubMed ID: 34794379
[TBL] [Abstract][Full Text] [Related]
15. Identification of a Stable, Non-Canonically Regulated Nrf2 Form in Lung Cancer Cells.
Mikac S; Rychłowski M; Dziadosz A; Szabelska-Beresewicz A; Fahraeus R; Hupp T; Sznarkowska A
Antioxidants (Basel); 2021 May; 10(5):. PubMed ID: 34063559
[TBL] [Abstract][Full Text] [Related]
16. Cooperation between NRF2-mediated transcription and MDIG-dependent epigenetic modifications in arsenic-induced carcinogenesis and cancer stem cells.
Bi Z; Zhang Q; Fu Y; Seno A; Wadgaonkar P; Qiu Y; Almutairy B; Xu L; Zhang W; Thakur C; Chen F
Semin Cancer Biol; 2021 Nov; 76():310-318. PubMed ID: 33823236
[TBL] [Abstract][Full Text] [Related]
17. Autophagy Triggers Tamoxifen Resistance in Human Breast Cancer Cells by Preventing Drug-Induced Lysosomal Damage.
Actis C; Muzio G; Autelli R
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809171
[TBL] [Abstract][Full Text] [Related]
18. Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells.
Duan L; Calhoun S; Shim D; Perez RE; Blatter LA; Maki CG
J Mol Cell Biol; 2021 Sep; 13(6):433-444. PubMed ID: 33755174
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
